Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with non-intervention of antifibrotic agents in IPF patients.
Asami-Noyama M, Hamada K, Asai Y, Abe T, Yonezawa K, Watanabe M, Hisamoto Y, Murakawa K, Fukatsu A, Matsuda K, Ohata S, Suetake R, Murata Y, Yamaji Y, Oishi K, Edakuni N, Hirano T, Kakugawa T, Matsunaga K. Asami-Noyama M, et al. Among authors: ohata s. Respir Investig. 2024 Nov;62(6):1124-1131. doi: 10.1016/j.resinv.2024.09.008. Epub 2024 Oct 2. Respir Investig. 2024. PMID: 39362180 Free article.
Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476].
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H. Koyama T, et al. Among authors: ohata s. ESMO Open. 2024 Aug;9(8):103652. doi: 10.1016/j.esmoop.2024.103652. Epub 2024 Jul 20. ESMO Open. 2024. PMID: 39033684 Free PMC article. No abstract available.
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima M, Shinomiya H, Minami H. Koyama T, et al. Among authors: ohata s. ESMO Open. 2024 Jun;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833968 Free PMC article. Clinical Trial.
108 results